At a glance
ClinicalIndex Comparison RecordEarly Ph 1Active· 20 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma
In Brief
A Early Phase 1 clinical trial evaluating Laboratory Biomarker Analysis and Pembrolizumab for Smoldering Plasma Cell Myeloma. Active but no longer recruiting, targeting 20 participants across 1 site.
Detailed Summary
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoldering Plasma Cell Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Early Ph 1Active
2016201720182019202020212022202320242025202620272028
First PostedNov 2015
Enrollment StartJul 2016
Primary CompletionDec 2017
TodayJul 2026
Study CompletionDec 2027
First PostedNov 13, 2015
Enrollment StartJul 20, 2016
Primary CompletionDec 30, 2017
Study CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.6 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pembrolizumabbiological
Given IV